Full details, including potential risk factors, are given in the Press Release, which can be consulted by clicking on the link below
BAUSCH HEALTH ANNOUNCES VYZULTA (LATANOPROSTENE BUNOD OPHTHALMIC SOLUTION), 0.024%, IS NOW APPROVED IN SEVEN COUNTRIES

September 24, 2020

View Press Release Corporate presentation Contact us
Previous